tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2020 Jun 6;85:106683.
doi: 10.1016/j.intimp.2020.106683. Online ahead of print.
Neutrophil to CD4+ Lymphocyte Ratio as a Potential Biomarker in Predicting Virus Negative Conversion Time in COVID-19
Haizhou Wang[SUP] 1 [/SUP], Yongxi Zhang[SUP] 2 [/SUP], Pingzheng Mo[SUP] 2 [/SUP], Jing Liu[SUP] 1 [/SUP], Hongling Wang[SUP] 1 [/SUP], Fan Wang[SUP] 3 [/SUP], Qiu Zhao[SUP] 4 [/SUP]
Affiliations
Abstract
Background: Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. Our study aimed to evaluate the robustness of neutrophil to CD4+ lymphocyte ratio (NCD4LR) in predicting the negative conversion time (NCT) of SARS-CoV-2 in COVID-19 patients.
Methods: Univariate and multivariate analysis were conducted to evaluate the independency of NCD4LR in predicting NCT. Receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) were used to assess the diagnostic accuracy.
Results: Compared with low NCD4LR patients, patients with high NCD4LR had an older age; higher incidence of fever, fatigue, chest distress/breath shortness, severer disease assessment on admission; higher levels of inflammatory indicators; low levels of lymphocyte subsets, and a longer NCT. Multivariate analysis also identified NCD4LR as an independent risk factor for delayed NCT. ROC analysis showed that NCD4LR had a better performance than neutrophil to lymphocyte ratio in predicting the virus negative conversion within 2 weeks (AUC = 0.772), 3 weeks (AUC = 0.710), 4 weeks (AUC = 0.728), or 5 weeks (AUC = 0.815).
Conclusion: This study suggests that NCD4LR is a potential and useful biomarker for predicting the virus negative conversion time in COVID-19 patients. Furthermore, due to the NCDLR value is easily calculated, it can be widely used as a clinical biomarker for disease progression and clinical outcomes in COVID-19 patients.
Keywords: COVID-19; Negative conversion time; Neutrophil to CD4+ lymphocyte ratio; SARS-CoV-2.
. 2020 Jun 6;85:106683.
doi: 10.1016/j.intimp.2020.106683. Online ahead of print.
Neutrophil to CD4+ Lymphocyte Ratio as a Potential Biomarker in Predicting Virus Negative Conversion Time in COVID-19
Haizhou Wang[SUP] 1 [/SUP], Yongxi Zhang[SUP] 2 [/SUP], Pingzheng Mo[SUP] 2 [/SUP], Jing Liu[SUP] 1 [/SUP], Hongling Wang[SUP] 1 [/SUP], Fan Wang[SUP] 3 [/SUP], Qiu Zhao[SUP] 4 [/SUP]
Affiliations
- PMID: 32531713
- PMCID: PMC7275184
- DOI: 10.1016/j.intimp.2020.106683
Abstract
Background: Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. Our study aimed to evaluate the robustness of neutrophil to CD4+ lymphocyte ratio (NCD4LR) in predicting the negative conversion time (NCT) of SARS-CoV-2 in COVID-19 patients.
Methods: Univariate and multivariate analysis were conducted to evaluate the independency of NCD4LR in predicting NCT. Receiver operating characteristic (ROC) curve analysis and area under the curve (AUC) were used to assess the diagnostic accuracy.
Results: Compared with low NCD4LR patients, patients with high NCD4LR had an older age; higher incidence of fever, fatigue, chest distress/breath shortness, severer disease assessment on admission; higher levels of inflammatory indicators; low levels of lymphocyte subsets, and a longer NCT. Multivariate analysis also identified NCD4LR as an independent risk factor for delayed NCT. ROC analysis showed that NCD4LR had a better performance than neutrophil to lymphocyte ratio in predicting the virus negative conversion within 2 weeks (AUC = 0.772), 3 weeks (AUC = 0.710), 4 weeks (AUC = 0.728), or 5 weeks (AUC = 0.815).
Conclusion: This study suggests that NCD4LR is a potential and useful biomarker for predicting the virus negative conversion time in COVID-19 patients. Furthermore, due to the NCDLR value is easily calculated, it can be widely used as a clinical biomarker for disease progression and clinical outcomes in COVID-19 patients.
Keywords: COVID-19; Negative conversion time; Neutrophil to CD4+ lymphocyte ratio; SARS-CoV-2.